Details of the Drug

General Information of Drug (ID: DML2NIB)

Drug Name
Aminophylline
Synonyms
Aminocardol; Aminodur; Aminofilina; Aminofillina; Aminophyllin; Ammophyllin; Cardiofilina; Cardiomin; Cardophylin; Cardophyllin; Carena; Cariomin; DOBO; Diaphilline; Diaphyllin; Diaphylline; Diophllin; Diophyllin; Diuxanthine; Ethophylline; Eufilina; Euphyllin; Euphylline; Euphyllinum; Eurphyllin; Euufilin; Euufillin; Genophyllin; Grifomin; Inophylline; Lasodex; Linampheta; Lixaminol; Metaphyllin; Metaphylline; Minaphil; Miofilin; Neophyiline; Norofilina; Peterphyllin; Phylcardin; Phyllindon; Phyllocontin; Phyllotemp; Somophyllin; Stenovasan; Syntophyllin; Theodrox; Theolamine; Theolone; Theomin; Theophyldine; Thephyldine; Truphylline; Vasofilina; A 1755; BY 108; Minomal(TN); Phyllocontin (TN); TH/100; Truphylline (TN)
Indication
Disease Entry ICD 11 Status REF
Bronchial asthma CA23 Approved [1]
Bronchitis CA20 Approved [2]
Lung cancer 2C25.0 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [2]
Pulmonary disease 1B10-1F85 Approved [2]
Pulmonary emphysema CA21.Z Approved [2]
Severe asthma CA23 Approved [2]
Asthma CA23 Phase 2 [3]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Bronchodilator Agents
Affected Organisms
Humans and other mammals
ATC Code
R03DA05: Aminophylline
R03DA: Xanthines
R03D: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03: DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R: RESPIRATORY SYSTEM
R03DA05: Aminophylline
R03DA: Xanthines
R03D: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03: DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R: RESPIRATORY SYSTEM
R03DA05: Aminophylline
R03DA: Xanthines
R03D: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03: DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R: RESPIRATORY SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski):
0		 Molecular Weight 420.43
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 1
Hydrogen Bond Donor Count 4
Hydrogen Bond Acceptor Count 8
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 7 - 9 hours [4]
Vd
The volume of distribution (Vd) of drug is 0.3-0.7 L/kg []
Chemical Identifiers
Formula
C16H24N10O4
IUPAC Name
1,3-dimethyl-7H-purine-2,6-dione;ethane-1,2-diamine
Canonical SMILES
CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N
InChI
InChI=1S/2C7H8N4O2.C2H8N2/c2*1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;3-1-2-4/h2*3H,1-2H3,(H,8,9);1-4H2
InChIKey
FQPFAHBPWDRTLU-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
9433
ChEBI ID
CHEBI:2659
CAS Number
317-34-0
UNII
27Y3KJK423
DrugBank ID
DB01223
TTD ID
D03TYI
INTEDE ID
DR0090
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 3A (PDE3A) TT06AWU PDE3A_HUMAN Inhibitor [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [6]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Aminophylline (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Decreased metabolism of Aminophylline caused by Metreleptin mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [8]
Emapalumab DMZG5WL Moderate Altered metabolism of Aminophylline due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [9]
Siltuximab DMGEATB Moderate Altered metabolism of Aminophylline due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [9]
Obeticholic acid DM3Q1SM Moderate Decreased metabolism of Aminophylline caused by Obeticholic acid mediated inhibition of CYP450 enzyme. Autoimmune liver disease [DB96] [10]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Aminophylline caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [11]
Tucatinib DMBESUA Moderate Decreased metabolism of Aminophylline caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [12]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Aminophylline caused by Levonorgestrel. Contraceptive management [QA21] [13]
Stiripentol DMMSDOY Moderate Decreased metabolism of Aminophylline caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [14]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Aminophylline caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [15]
Cannabidiol DM0659E Moderate Increased metabolism of Aminophylline caused by Cannabidiol mediated induction of CYP450 enzyme. Epileptic encephalopathy [8A62] [16]
Febuxostat DMDEXQ0 Moderate Decreased metabolism of Aminophylline caused by Febuxostat mediated inhibition of non-CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [17]
Amobarbital DM0GQ8N Moderate Increased metabolism of Aminophylline caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [18]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Aminophylline and Polyethylene glycol. Irritable bowel syndrome [DD91] [19]
Blinatumomab DMGECIJ Moderate Decreased metabolism of Aminophylline caused by Blinatumomab mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [20]
Exjade DMHPRWG Major Decreased metabolism of Aminophylline caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [21]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Aminophylline due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [9]
Ixekizumab DMXW92T Moderate Altered metabolism of Aminophylline due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [9]
Tocilizumab DM7J6OR Moderate Altered metabolism of Aminophylline due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [9]
Canakinumab DM8HLO5 Moderate Altered metabolism of Aminophylline due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [9]
Rilonacept DMGLUQS Moderate Altered metabolism of Aminophylline due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [9]
Golimumab DMHZV7X Moderate Altered metabolism of Aminophylline due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [9]
Sarilumab DMOGNXY Moderate Altered metabolism of Aminophylline due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [9]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Aminophylline caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [22]
⏷ Show the Full List of 23 DDI Information of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 081142.
2 Aminophylline FDA Label
3 Adenosine receptors: development of selective agonists and antagonists. Prog Clin Biol Res. 1987;230:41-63.
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Topical fat reduction from the waist. Diabetes Obes Metab. 2007 May;9(3):300-3.
6 Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther. 1996 Mar;276(3):912-7.
7 Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. Pharmacotherapy. 1998 Nov-Dec;18(6):1237-48.
8 Product Information. Myalept (metreleptin). Bristol-Myers Squibb, Princeton, NJ.
9 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10 Product Information. Ocaliva (obeticholic acid). Intercept Pharmaceuticals, Inc., New York, NY.
11 Amsden GW "Erythromycin, clarithromycin, and azithromycin: are the differences real?" Clin Ther 18 (1996): 56-72. [PMID: 8851453]
12 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
13 Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R "Effects of tobacco smoking and oral contraceptive use on theophylline disposition." Br J Clin Pharmacol 16 (1983): 271-80. [PMID: 6626419]
14 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
15 Crowley JJ, Cusack BJ, Jue SG, et al "Cigarette smoking and theophylline metabolism: effects of phenytoin." Clin Pharmacol Ther 42 (1987): 334-40. [PMID: 3621789]
16 Cerner Multum, Inc. "Australian Product Information.".
17 Product Information. Uloric (febuxostat). Takeda Pharmaceuticals America, Lincolnshire, IL.
18 Bukowskyj M, Nakatsu K, Munt PW "Theophylline reassessed." Ann Intern Med 101 (1984): 63-73. [PMID: 6145380]
19 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
20 Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
21 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
22 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.